3,863
Views
22
CrossRef citations to date
0
Altmetric
Special Report

Nitric Oxide Therapy for Dermatologic Disease

&
Article: FSO37 | Published online: 27 Jul 2015

Figures & data

Figure 1. Infected full-thickness dermal wounds on New Zealand white rabbit ears.

Ischemic (I) and nonischemic (N) wounds were treated with NO probiotic patch or control patch at days 1, 13, and 20 postsurgery.

gNO: Gaseous nitric oxide.

Reproduced with permission from [Citation39]. © John Wiley & Sons, Inc. (2012).

Figure 1.  Infected full-thickness dermal wounds on New Zealand white rabbit ears.Ischemic (I) and nonischemic (N) wounds were treated with NO probiotic patch or control patch at days 1, 13, and 20 postsurgery.gNO: Gaseous nitric oxide.Reproduced with permission from [Citation39]. © John Wiley & Sons, Inc. (2012).

Figure 2. Methicillin-resistant Staphylococcus aureus-infected full-thickness wounds in mice at days 3 and 7: untreated, treated with empty nanoparticles and treated with nitric oxide nanoparticles.

NO: Nitric oxide; np: Nanoparticle.

Reproduced with permission from [Citation46]. © Macmillan Publishers Ltd. (2009).

Figure 2.  Methicillin-resistant Staphylococcus aureus-infected full-thickness wounds in mice at days 3 and 7: untreated, treated with empty nanoparticles and treated with nitric oxide nanoparticles.NO: Nitric oxide; np: Nanoparticle.Reproduced with permission from [Citation46]. © Macmillan Publishers Ltd. (2009).

Figure 3. Burn wounds infected with Candida albicans: untreated, treated with empty nanoparticles, and treated with nitric oxide nanoparticles, at days 0, 1, 5, 10 and 15.

Scale bar: 5 mm.

NO: Nitric oxide; np: Nanoparticle.

Reproduced with permission from [Citation48]. © Macherla C, Sanchez DA, Ahmadi MS et al. (2012).

Figure 3.  Burn wounds infected with Candida albicans: untreated, treated with empty nanoparticles, and treated with nitric oxide nanoparticles, at days 0, 1, 5, 10 and 15.Scale bar: 5 mm.NO: Nitric oxide; np: Nanoparticle.Reproduced with permission from [Citation48]. © Macherla C, Sanchez DA, Ahmadi MS et al. (2012).

Figure 4. Methicillin-resistant Staphylococcus aureus-infected murine abscesses: untreated, treated with empty nanoparticles, and treated with nitric oxide nanoparticles at day 4.

Arrows denote abscesses. Inset: representative purulent abscess 4 days post-methicillin-resistant Staphylococcus aureus infection. Scale bar: 5 mm.

NO: Nitric oxide; np: Nanoparticle.

Reproduced with permission from [Citation49]. © Han et al. (2009).

Figure 4.  Methicillin-resistant Staphylococcus aureus-infected murine abscesses: untreated, treated with empty nanoparticles, and treated with nitric oxide nanoparticles at day 4.Arrows denote abscesses. Inset: representative purulent abscess 4 days post-methicillin-resistant Staphylococcus aureus infection. Scale bar: 5 mm.NO: Nitric oxide; np: Nanoparticle.Reproduced with permission from [Citation49]. © Han et al. (2009).

Figure 5. Pseudomonas aeruginosa-infected excisional wounds in mice: untreated, glutathione-treated, nitric oxide nanoparticle-treated and nitric oxide nanoparticle + glutathione-treated at days 1, 3 and 7.

Scale bar: 5 mm.

GSH: Glutathione; NO: Nitric oxide; np: Nanoparticle.

Reproduced with permission from [Citation52]. © J. Drugs Dermatol. (2012).

Figure 5.  Pseudomonas aeruginosa-infected excisional wounds in mice: untreated, glutathione-treated, nitric oxide nanoparticle-treated and nitric oxide nanoparticle + glutathione-treated at days 1, 3 and 7.Scale bar: 5 mm.GSH: Glutathione; NO: Nitric oxide; np: Nanoparticle.Reproduced with permission from [Citation52]. © J. Drugs Dermatol. (2012).

Figure 6. Role of reactive oxygen species in photoaging.

MMP: Matrix metalloproteinase; ROS: Reactive oxygen species.

Reprinted with permission from [Citation57]. © Elsevier (2004).

Figure 6.  Role of reactive oxygen species in photoaging.MMP: Matrix metalloproteinase; ROS: Reactive oxygen species.Reprinted with permission from [Citation57]. © Elsevier (2004).

Table 1.  Antimicrobial activities of nitric oxide-releasing platforms.